Aksys’ PHD
This article was originally published in The Gray Sheet
Executive Summary
Personal hemodialysis system gains 510(k) clearance for home use. Initial launch efforts for the firm's first product will focus on the northwest and midwest U.S., with shipments commencing in the third quarter. Aksys has projected it will achieve a roughly 5% share of a 375,000-patient U.S. dialysis patient market with the automated system within five years (1"The Gray Sheet" Feb. 5, 2001, p. 11)...
You may also be interested in...
Aksys Projects $400 Mil. In PHD Hemodialysis System Revenues By 2006
Aksys expects PHD personal hemodialysis system revenues in the U.S. to reach approximately $400 mil. by 2006.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.